New obesity drug combo enters early human testing

NCT ID NCT06151964

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug combination (AZD9550 and AZD6234) for weight loss in 166 adults who are overweight or obese, with or without type 2 diabetes. The main goals are to check safety, tolerability, and how the drug moves through the body. It is an early-stage trial, so it focuses on finding the right dose and ensuring the drug is safe before testing if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD9550 (a dual GCG/GLP-1 receptor agonist) and AZD6234 (a SARA)
What this could lead to: If successful, this could lead to a new weight-loss treatment that also helps control blood sugar in people with type 2 diabetes.
What could go wrong: This is an early Phase 1/2 trial focused on safety and dosing, not effectiveness. The drug may cause side effects or fail to show meaningful weight loss in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder Overweight type 2 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC STEATOHEPATITIS (NASH) OVERWEIGHT AND OBESITY

Contacts and locations

Locations

Research Site

Graz, 8036, Austria
Research Site

Vienna, 1090, Austria
Research Site

Surrey, British Columbia, V3T 4G8, Canada
Research Site

Hamilton, Ontario, L8L 5G8, Canada
Research Site

Sarnia, Ontario, N7T 4X3, Canada
Research Site

Stouffville, Ontario, L4A 1H2, Canada
Research Site

Toronto, Ontario, M4G 3E8, Canada
Research Site

Sherbrooke, Quebec, J1L 0H8, Canada
Research Site

Magdeburg, 39120, Germany
Research Site

Neu-Ulm, 89231, Germany
Research Site

Neuss, 41460, Germany
Research Site

Fukuoka, 812-0025, Japan
Research Site

Shinjuku-ku, 160-0004, Japan
Research Site

Suita-shi, 565-0853, Japan
Research Site

Uppsala, 752 37, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.